← All trials
NCT01804361
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2013
- Primary completion
- Feb 1, 2014
- Completion date
- Feb 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- DH Bio Co., Ltd.Lead sponsor
- Seoul National UniversityOverall official - principal investigator
- Korea UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- BTO Pharm. Co., Ltd.Collaborator
- University of UlsanOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.